PDF(Pubmed)
Abstract：
UNASSIGNED: Acitretin is a synthetic, second-generation retinoid mainly used for the treatment of Darier\'s disease (DD), which impacts biological processes by binding to a nuclear receptor from the corticosteroid/thyroid receptor superfamily, thereby altering gene expression. Our report outlines the case of a 41-year-old male patient who has received a clinical diagnosis of DD and does not exhibit any other coexisting comorbidities, who developed hypothyroidism posttreatment with acitretin, an unusual and rare side effect of the drug. His baseline routine investigations fell within normal limits before the initiation of acitretin. Acitretin-induced hypothyroidism was treated with thyroxine. Although a good therapeutic response was seen with acitretin, it could not be continued due to the development of side effects and was continued on topical therapy. This case emphasizes the likelihood of adverse effects linked to therapeutic levels of acitretin in patients without any prior history and signifies the critical importance of consistent blood monitoring throughout drug therapy.
摘要：
■Acitretin是一种合成的，第二代类维生素A主要用于治疗达里尔病（DD），通过与皮质类固醇/甲状腺受体超家族的核受体结合来影响生物过程，从而改变基因表达。我们的报告概述了一名41岁的男性患者，他接受了DD的临床诊断，没有表现出任何其他共存的合并症，阿维A治疗后出现甲状腺功能减退症，这种药物的不寻常和罕见的副作用。在阿曲汀开始之前，他的基线常规检查落在正常范围内。阿维A诱导的甲状腺功能减退症用甲状腺素治疗。尽管阿曲汀有良好的治疗反应，由于副作用的发展，它无法继续，并继续在局部治疗。该病例强调了在没有任何既往病史的患者中与阿曲汀治疗水平相关的不良反应的可能性，并表明在整个药物治疗中持续进行血液监测的重要性。
